Showcasing latest AI updates, Insilico Medicine attends 2024 EFMC International Symposium on Medicinal Chemistry

Attracting around 1,000 participants from industry and academia, the XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) is supposed to take place in Rome, Italy from September 1-5, 2024. After the generative AI updates recently announced on the IMGAIA webinar, Insilico Medicine will be sharing more innovative details while exploring collaboration chances at Booth #50.

EFMC-ISMC is a key symposium in the field of medicinal chemistry and drug discovery, and the symposium this year features prizes and awards acknowledging the excellence of medicinal chemists’ work, as well as a wide coverage of selected topics including chemical biology, drug discovery projects, and technologies.

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) is an independent association founded in December 1969, representing 31 scientific organisations from 26 European countries, and more than 9000 scientists. By organizing symposia and short courses, sponsoring meetings and schools, and conferring awards, EFMC strives to establish links and to advance the science.

Founded in 2014, Insilico Medicine is a pioneer in using generative AI for drug discovery and development. Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016, which laid the foundation for the commercially available Pharma.AI platform spanning across biology, chemistry and clinical development. Powered by Pharma.AI, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021, and has received IND approval for 7 molecules. Recently, the company published a paper in Nature Biotechnology presenting the entire R&D journey of its lead drug pipeline, INS018_055, from AI algorithms to Phase II clinical trials.

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

www.insilico.com